This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Relapsed AML (acute myeloid leukaemia)

Authoring team

Relapse is seen in over 50% of patients (1).

  • in a majority of patients who achieve clinical remission, AML will recur within 3 years after diagnosis
  • the prognosis is poor and treatment options are unsatisfactory in this group of patients (2).

There is no established standard in the treatment of relapsed disease. The idea behind treatment of relapsed AML patients is to achieve a new remission.

Once a new remission has been achieved, allogeneic stem cell transplantation is the consolidation therapy of choice. An autologous HSCT is often regarded as the second best option in situations where an allogeneic HSCT is not possible due to lack of a suitable donor (2).

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.